-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, due to the difficulty, time-consuming, labor-intensive, and costly research and development of new drugs, many pharmaceutical companies have vigorously made some new investment arrangements in order to increase corporate operating profits, enrich drug pipelines, and reduce R&D expenditures
.
In this context, the pharmaceutical industry has also begun to frequently see large-scale mergers and acquisitions
.
Recently, Australian biomedical giant CSL announced that it will spend approximately US$11.
7 billion to acquire Swiss drugmaker Vifor Pharma
.
Through this acquisition, CSL will obtain a number of Vifor products under research and approval, supplementing CSL's existing product pipeline in the treatment of key areas, including cardiovascular metabolism, kidney disease, hematological diseases and transplantation technology
.
Specifically, CSL will obtain Vifor's product pipeline for the treatment of iron deficiency, kidney disease and heart and kidney disease
.
These include an oral ferroportin inhibitor vamifeport (VIT-2763), which is used to treat erythropoiesis and iron overload diseases, such as β-thalassemia or sickle cell anemia (SCD)
.
In addition, CSL will also become the co-owner of Korsuva (difelikefalin)
.
Korsuva, jointly developed by Vifor and Cara Therapeutics, is a "first-in-class" κ opioid receptor (KOR) agonist for the treatment of moderate to severe itching in adult patients with chronic kidney disease (CKD) undergoing dialysis
.
In August of this year, the therapy was approved by the FDA for the treatment of this patient group
.
Coincidentally, London-based quantum startup Rahko has also been acquired by Odyssey Therapeutics of the United States
.
According to the data, the company was founded in 2018 by a computer science graduate from University College London.
It is "solving drug discovery problems through quantum machine learning" and is developing a drug discovery service called Hyrax that applies drug discovery algorithms to quantum computers
.
From the perspective of the industry, in recent years, a large number of pharmaceutical companies are facing problems such as revenue growth pressure, patent expiration, and high cost of research and development of new drugs.
This has forced more and more large pharmaceutical companies to start accelerating mergers and acquisitions.
Enrich the product pipeline and stabilize the situation
.
At present, in addition to multinational companies, domestic pharmaceutical companies are also choosing mergers and acquisitions to continuously promote their own development in order to further improve their overall competitiveness, realize industrial integration and rationalize their structure
.
Statistics show that as of the end of September, China's pharmaceutical and biological industry has more than 100 mergers and acquisitions
.
Since the second half of the year, mergers and acquisitions in the domestic pharmaceutical industry are still active, and a large number of companies including Buchang Pharmaceuticals and Yuanda Pharmaceuticals have also issued merger announcements
.
For example, on October 14th, Buchang Pharmaceutical announced that the company and its wholly-owned subsidiary, Shenzhou Pharmaceutical, planned to acquire 100% of Beijing Chengrui, with a total transaction price of 271 million yuan
.
In September, Jiangzhong Pharmaceutical issued an announcement that it intends to acquire 51% of Hais Pharmaceuticals through equity transfer and capital increase; among them, it intends to acquire 36% of Hais Pharmaceuticals through public delisting (held by Jinneng Holding Equipment Manufacturing Group Co.
, Ltd.
) Some have a 25.
7102% stake in Hays Pharmaceuticals, and a 10.
2898% stake in Hays Pharmaceuticals held by Jincheng Wangtai Technology Industry and Trade Co.
, Ltd.
)
.
Based on the current industry trends, analysts believe that large pharmaceutical companies may increase their R&D pipelines, invest in blockbuster drugs under research or about to go on the market, and enhance the complementarity of their product portfolios and synergistic economies of scale.
M&A transactions, the total transaction is expected to exceed 1.
7 trillion US dollars
.
.
In this context, the pharmaceutical industry has also begun to frequently see large-scale mergers and acquisitions
.
Recently, Australian biomedical giant CSL announced that it will spend approximately US$11.
7 billion to acquire Swiss drugmaker Vifor Pharma
.
Through this acquisition, CSL will obtain a number of Vifor products under research and approval, supplementing CSL's existing product pipeline in the treatment of key areas, including cardiovascular metabolism, kidney disease, hematological diseases and transplantation technology
.
Specifically, CSL will obtain Vifor's product pipeline for the treatment of iron deficiency, kidney disease and heart and kidney disease
.
These include an oral ferroportin inhibitor vamifeport (VIT-2763), which is used to treat erythropoiesis and iron overload diseases, such as β-thalassemia or sickle cell anemia (SCD)
.
In addition, CSL will also become the co-owner of Korsuva (difelikefalin)
.
Korsuva, jointly developed by Vifor and Cara Therapeutics, is a "first-in-class" κ opioid receptor (KOR) agonist for the treatment of moderate to severe itching in adult patients with chronic kidney disease (CKD) undergoing dialysis
.
In August of this year, the therapy was approved by the FDA for the treatment of this patient group
.
Coincidentally, London-based quantum startup Rahko has also been acquired by Odyssey Therapeutics of the United States
.
According to the data, the company was founded in 2018 by a computer science graduate from University College London.
It is "solving drug discovery problems through quantum machine learning" and is developing a drug discovery service called Hyrax that applies drug discovery algorithms to quantum computers
.
From the perspective of the industry, in recent years, a large number of pharmaceutical companies are facing problems such as revenue growth pressure, patent expiration, and high cost of research and development of new drugs.
This has forced more and more large pharmaceutical companies to start accelerating mergers and acquisitions.
Enrich the product pipeline and stabilize the situation
.
At present, in addition to multinational companies, domestic pharmaceutical companies are also choosing mergers and acquisitions to continuously promote their own development in order to further improve their overall competitiveness, realize industrial integration and rationalize their structure
.
Statistics show that as of the end of September, China's pharmaceutical and biological industry has more than 100 mergers and acquisitions
.
Since the second half of the year, mergers and acquisitions in the domestic pharmaceutical industry are still active, and a large number of companies including Buchang Pharmaceuticals and Yuanda Pharmaceuticals have also issued merger announcements
.
For example, on October 14th, Buchang Pharmaceutical announced that the company and its wholly-owned subsidiary, Shenzhou Pharmaceutical, planned to acquire 100% of Beijing Chengrui, with a total transaction price of 271 million yuan
.
In September, Jiangzhong Pharmaceutical issued an announcement that it intends to acquire 51% of Hais Pharmaceuticals through equity transfer and capital increase; among them, it intends to acquire 36% of Hais Pharmaceuticals through public delisting (held by Jinneng Holding Equipment Manufacturing Group Co.
, Ltd.
) Some have a 25.
7102% stake in Hays Pharmaceuticals, and a 10.
2898% stake in Hays Pharmaceuticals held by Jincheng Wangtai Technology Industry and Trade Co.
, Ltd.
)
.
Based on the current industry trends, analysts believe that large pharmaceutical companies may increase their R&D pipelines, invest in blockbuster drugs under research or about to go on the market, and enhance the complementarity of their product portfolios and synergistic economies of scale.
M&A transactions, the total transaction is expected to exceed 1.
7 trillion US dollars
.
